- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04359680
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
December 5, 2023 updated by: Romark Laboratories L.C.
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Study Type
Interventional
Enrollment (Actual)
1407
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- HealthStar Research LLC
-
-
California
-
Huntington Beach, California, United States, 92647
- So Cal Clinical Research
-
Long Beach, California, United States, 90806
- Long Beach Clinical Trials, LLC
-
-
Florida
-
Brandon, Florida, United States, 33511
- Meris Clinical Research
-
Fort Lauderdale, Florida, United States, 33308
- Invesclinica US LLC
-
Kissimmee, Florida, United States, 34744
- The Chappel Group Research
-
Miami, Florida, United States, 33165
- New Horizon Research Center
-
Orlando, Florida, United States, 32801
- Clinical Neuroscience Solutions, Inc.
-
Pinellas Park, Florida, United States, 33782
- DMI Research
-
Tampa, Florida, United States, 33606
- Tampa General Hospital
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Chicago Clinical Research Institute, Inc.
-
Chicago, Illinois, United States, 60607
- Chicago Medical Research Institute, Inc.
-
Chicago, Illinois, United States, 60643
- Quad Clinical Research
-
Hazel Crest, Illinois, United States, 60429
- Chicago Medical Research, LLC
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70601
- Centex Studies, Inc.
-
-
Michigan
-
Dearborn, Michigan, United States, 48124
- Vida Clinical Studies
-
-
Nebraska
-
Fremont, Nebraska, United States, 68025
- Beacom Family Health Connection
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- North Jersey Community Research Initiative
-
-
New York
-
Bronx, New York, United States, 10456
- RH Medical Urgent Care Professional PLLC
-
Brooklyn, New York, United States, 11229
- Integrative Clinical Trials LLC
-
New York, New York, United States, 10022
- The New York Center for Travel and Tropical Medicine
-
-
Texas
-
Houston, Texas, United States, 77058
- Centex Studies, Inc.
-
Mesquite, Texas, United States, 75149
- SMS Clinical Research LLC
-
Pearland, Texas, United States, 77584
- LINQ Research LLC
-
Pharr, Texas, United States, 78577
- Rio Grande Valley Clinical Research Institute
-
San Antonio, Texas, United States, 78249
- BFHC Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 120 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males and females at least 18 years of age or of legal consenting age based on local requirements.
Persons at increased risk of contracting COVID-19, including:
- Healthcare workers with known direct occupational exposure to COVID-19 within 7 days prior to enrollment. A qualifying person (i) provides healthcare to patients and/or (ii) typically positions themselves within 6 feet of patients ("close contact") and (iii) is a full- time employee (average of ≥ 24 hours/week) in a high contact area (Emergency Department, Intensive Care Unit, COVID-specific Care Unit, Walk-in Clinic, Paramedic/First Responder).
- Persons participating in social activities without the practice of generally accepted social distancing practices at least three times per week. Qualifying activities include the presence of at least 10 people in close (<6 feet) proximity to each other without masks or other personal protective equipment (e.g., socializing at bars or community/social centers, in-home social gatherings, classes or trainings, etc.). These subjects must have engaged in such activities at least three times in the past 7 days and plan to continue these activities during the study.
- Must have a smartphone, tablet, computer, or other qualifying internet- enabled device and daily internet access.
- Occupational exposure to a person infected with SAR-CoV-2 within 7 days prior to enrollment or social interaction as defined in criterion 2(b).
- Willing and able to provide written informed consent and comply with the requirements of the protocol, including completion of the subject diary.
Exclusion Criteria:
- Subjects not at increased risk of contracting SARS-CoV-2 from occupational or social behaviors.
- Subjects with known severe heart, lung, neurological or other systemic disease that the Investigator believes could preclude safe participation.
- Subjects with a history of COVID-19 or known to have developed anti- SARS-CoV-2 antibodies or received a SARS-CoV-2 vaccine.
- Subjects who experienced a previous episode of acute upper respiratory tract infection, otitis, bronchitis or sinusitis or received antibiotics for these conditions or antiviral therapy for influenza within two weeks prior to and including study day 1.
- Subjects residing in the same household with another family member currently participating in the study.
- Receipt of any dose of NTZ within 7 days prior to screening.
- Treatment with any investigational drug or vaccine therapy within 30 days prior to screening and willing to avoid them during the course of the study.
- Known sensitivity to NTZ or any of the excipients comprising the study medication.
- Subjects unable to swallow oral tablets or capsules.
- Females of childbearing potential who are either pregnant or sexually active without the use of birth control. Female subjects of child-bearing potential that are sexually active must have a negative baseline pregnancy test and must agree to continue an acceptable method of birth control for the duration of the study and for 1 month post-treatment. A double barrier method, oral birth control pills administered for at least 2 monthly cycle prior to study drug administration, an (intrauterine device) IUD, or medroxyprogesterone acetate administered intramuscularly for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year or 6 months if laboratory confirmation of hormonal status), or have had a hysterectomy, bilateral tubular ligation or bilateral oophorectomy.
- Females who are breastfeeding.
- Subjects with active respiratory allergies or subjects expected to require anti-allergy medications during the study period for respiratory allergies.
- Subjects taking medications considered to be major CYP2C8 substrates.
- Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol including completion of the subject diary.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nitazoxanide
Two NTZ 300 mg tablets orally twice daily for 6 weeks.
|
Vitamin Super B-Complex administered orally twice daily to maintain the blind
Nitazoxanide 600 mg administered orally twice daily for six weeks
Other Names:
|
Placebo Comparator: Placebo
Two placebo tablets orally twice daily for 6 weeks.
|
Vitamin Super B-Complex administered orally twice daily to maintain the blind
Placebo administered orally twice daily for six weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.
Time Frame: Up to 6 weeks
|
Up to 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 13, 2020
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
May 1, 2024
Study Registration Dates
First Submitted
April 20, 2020
First Submitted That Met QC Criteria
April 20, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Estimated)
December 7, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RM08-3007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Vitamin Super B-Complex
-
Hamad Medical CorporationHeidelberg University; Qatar UniversityCompletedAutism Spectrum Disorders | Stable Clinical Condition in the Last 3 MonthsQatar
-
Romark Laboratories L.C.Not yet recruiting
-
Medical University of GrazCompletedHealthy | Oxidative Stress | Vitamin B 12 Deficiency | Polyphenols | Thiamine and Niacin Deficiency States | Pyridoxine Deficiency | Folic Acid Deficiency Anemia, Dietary | Peroxidase; Defect | Homocystine; Metabolic DisorderAustria
-
Romark Laboratories L.C.RecruitingRhinovirus | EnterovirusUnited States
-
Romark Laboratories L.C.TerminatedCOVID-19 | Viral Respiratory IllnessesUnited States
-
Romark Laboratories L.C.Completed
-
Peking UniversityNational Natural Science Foundation of China; Institute of reproductive and...CompletedHyperhomocysteinemiaChina
-
Menzies School of Health ResearchCompleted
-
Romark Laboratories L.C.Not yet recruiting
-
University of FloridaNational Center for Research Resources (NCRR)CompletedDisorder of Vitamin B12United States